Oxford BioTherapeutics makes C Glenn Begley a director
This article was originally published in Scrip
Oxford BioTherapeutics, a biotech developing antibody-based cancer medicines, has appointed Dr C Glenn Begley a senior clinical advisor and non-executive director. Dr Begley, who previously served as vice-president and global head of haematology and oncology research at Amgen, will take a key role in shaping and executing OBT's clinical and corporate strategy.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.